Neil Lindsay Berkley Sells 29,251 Shares of Alector (NASDAQ:ALEC) Stock

Alector, Inc. (NASDAQ:ALEC) CFO Neil Berkley sold 29,251 shares of the firm’s stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $2.66, for a total transaction of $77,807.66. Following the completion of the sale, the chief financial officer owned 350,649 shares in the company, valued at approximately $932,726.34. The trade was a 7.70% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Alector Price Performance

ALEC stock opened at $2.46 on Friday. The company has a 50 day simple moving average of $1.91 and a 200 day simple moving average of $2.06. The stock has a market cap of $274.68 million, a price-to-earnings ratio of -2.24 and a beta of 0.65. Alector, Inc. has a 1 year low of $1.09 and a 1 year high of $3.40. The company has a debt-to-equity ratio of 0.80, a current ratio of 5.26 and a quick ratio of 5.26.

Alector (NASDAQ:ALEC) last issued its earnings results on Thursday, August 6th. The company reported ($0.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.02. The firm had revenue of $3.32 million for the quarter, compared to analyst estimates of $1.71 million. Alector had a negative net margin of 850.13% and a negative return on equity of 531.03%. Research analysts anticipate that Alector, Inc. will post -0.87 EPS for the current fiscal year.

Institutional Investors Weigh In On Alector

A number of institutional investors have recently made changes to their positions in the stock. Prudential Financial Inc. bought a new position in shares of Alector during the second quarter worth about $30,000. Hershey Trust Co. increased its position in Alector by 100.0% during the 4th quarter. Hershey Trust Co. now owns 20,572 shares of the company’s stock valued at $32,000 after purchasing an additional 10,286 shares during the period. Virtu Financial LLC bought a new position in Alector during the 4th quarter worth approximately $34,000. The Manufacturers Life Insurance Company bought a new position in Alector during the 2nd quarter worth approximately $39,000. Finally, Dynamic Technology Lab Private Ltd acquired a new position in shares of Alector in the 4th quarter worth approximately $40,000. Institutional investors own 85.83% of the company’s stock.

Analyst Ratings Changes

ALEC has been the topic of a number of recent research reports. Weiss Ratings raised Alector from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 13th. Wall Street Zen upgraded shares of Alector from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Three analysts have rated the stock with a Buy rating, three have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $3.62.

Alector Company Profile

Alector is a clinical-stage biotechnology company headquartered in South San Francisco, California. Founded in 2013, the company is focused on discovering and developing immuno-neurology therapies that target the innate immune system to treat a range of neurodegenerative disorders. Alector’s approach aims to harness the body’s natural defense mechanisms to clear pathological proteins and restore neuronal function in conditions such as Alzheimer’s disease and frontotemporal dementia.

The company’s pipeline includes multiple product candidates in both preclinical and clinical stages, with lead programs AL001 and AL002 advancing in frontotemporal dementia and Alzheimer’s disease studies.